Abstract Library

#4516 A methylation-based classifier for neuroendocrine tumour detection using smMIP technology

Introduction: DNA methylation plays an important role in NET pathogenesis. Distinct methylation profiles can differentiate between tumour subtypes, predict malignancy potential, and provide insights into tumour progression.

Conference:

Presenting Author:

Authors: Ibrahim J, Mariën L, Vanpoucke T, Neefs I, Vandenhoeck J,

Keywords: neuroendocrine tumour, DNA methylation, biomarker selection, IMPRESS technology, classifier model,

#4505 NET-IMPRESS: A novel methylation-based assay to diagnose and monitor NET patients using liquid biopsies

Introduction: Previously, we showed that analysing copy number alterations (CNAs) in cell-free DNA (cfDNA) of NET patients using shallow whole genome sequencing (sWGS) is a potential biomarker for diagnosis and follow-up (PMID: 34759042). We now present NET-IMPRESS, an easy, cost-effective methylation-based assay for detecting circulating tumour DNA (ctDNA) in NET samples.

Conference:

Presenting Author:

Authors: Mariën L, Ibrahim J, de Meulenaere N, Chhajlani S, Neefs I,

Keywords: neuroendocrine tumour, liquid biopsy, DNA methylation, copy number alterations, biomarker selection, IMPRESS technology,

#4165 Detecting NET using Methylation-based biomarkers and the novel IMPRESS technology

Introduction: Due to current limitations, diagnosis of neuroendocrine tumors (NETs) is frequently delayed. Addressing this issue is crucial, necessitating the identification of new, adequate biomarkers. Our previous work highlighted the methylome as a promising source of biomarkers, enabling differentiation of NET vs. non-NET samples, and distinguishing based on tissue of origin (TOO).

Conference:

Presenting Author: Mariën L

Authors: Mariën L, Ibrahim J, Islam O, Chhajlani S, Neefs I,

Keywords: neuroendocrine tumor, DNA methylation, biomarker selection, IMPRESS technology,

#3876 Comprehensive characterization of the NET methylome

Introduction: The methylome holds great promise for biomarker discovery in neuroendocrine tumors (NETs), as changes in DNA methylation allow differentiation into relevant subgroups and reveal tissue of origin. However, a comprehensive characterization of the NET methylome is lacking, hampering biological insight and meaningful biomarker selection.

Conference:

Presenting Author: Mariën L

Authors: Mariën L, Ibrahim J, Cremers T, Lybaert W, Prenen H,

Keywords: neuroendocrine tumor, DNA methylation, pathway analysis, biomarker selection,

#3422 Longitudinal copy number alteration analysis in plasma cell-free DNA of neuroendocrine neoplasms is a novel specific biomarker for diagnosis, prognosis and follow-up

Introduction: Research on liquid biopsies in neuroendocrine neoplasms (NENs) remains limited, despite the urgent need for new, preferably blood-based, biomarkers. Copy number alterations (CNAs) represent an important type of molecular alteration in NENs and are detectable in cell-free DNA (cfDNA).

Conference:

Presenting Author:

Authors: Mariën L, Boons G, Vandamme T, Lybaert W, Roeyen G,

Keywords: neuroendocrine neoplasm, liquid biopsies, circulating tumor DNA, biomarker, copy number alterations,